FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.92
+1.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 36.7M | 30.9M | 22.6M | 34.2M | 19.2M |
| Cost of Revenue | 21.0M | 3.3M | — | — | — |
| Gross Profit | 15.7M | 27.6M | 22.6M | 34.2M | 19.2M |
| Operating Expenses | |||||
| R&D Expense | 79.7M | 85.5M | 94.5M | 109.7M | 105.6M |
| SG&A Expense | 26.4M | 27.6M | 28.4M | 32.4M | 30.7M |
| General & Admin Expense | 26.4M | 27.6M | 28.4M | 32.4M | 30.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (21.9M) | (3.3M) | 2.4M | — | — |
| Total Operating Expenses | 84.2M | 109.7M | 125.3M | 142.1M | 136.4M |
| Cost and Expenses | 105.2M | 113.0M | 125.3M | 142.1M | 136.4M |
| Operating Income (EBIT) | (68.5M) | (82.1M) | (102.7M) | (107.9M) | (117.1M) |
| Non-Operating | |||||
| Interest Income | 7.1M | 8.7M | 11.9M | 10.9M | 5.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 7.1M | 8.7M | 11.9M | 10.9M | 5.7M |
| Other Non-Op Income/Expense | 3.9M | 7.8M | 16.1M | 13.7M | 8.3M |
| Non-Operating Income (excl Interest) | (3.9M) | (7.8M) | (2.4M) | (13.7M) | (8.3M) |
| EBT (Pre-Tax Income) | (64.6M) | (74.3M) | (86.6M) | (94.2M) | (108.9M) |
| Income Tax Expense | — | — | — | 4.2M | — |
| Bottom Line | |||||
| Net Income | (64.6M) | (74.3M) | (86.6M) | (98.4M) | (108.9M) |
| Earnings from Cont. Ops | (64.6M) | (74.3M) | (86.6M) | (98.4M) | (108.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (64.6M) | (74.3M) | (86.6M) | (98.4M) | (108.9M) |
| Per Share | |||||
| Basic EPS | ($0.99) | ($1.18) | ($1.58) | ($2.34) | ($2.62) |
| Diluted EPS | ($0.99) | ($1.18) | ($1.58) | ($2.34) | ($2.62) |
| Revenue Per Share | $0.52 | $0.49 | $0.41 | $0.81 | $0.46 |
| Shares | |||||
| Basic Shares Outstanding | 70.6M | 63.0M | 54.9M | 42.0M | 41.6M |
| Diluted Shares Outstanding | 70.6M | 63.0M | 54.9M | 42.0M | 41.6M |
| Profitability Metrics | |||||
| EBITDA | (62.5M) | (71.0M) | (97.2M) | (90.7M) | (105.6M) |
| D&A | 2.1M | 3.3M | 3.1M | 3.5M | 3.3M |
| EBIT | (64.6M) | (74.3M) | (100.3M) | (94.2M) | (108.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026